Fact-finding survey of antithrombotic treatment for prevention of cerebral and systemic thromboembolism in patients with non-valvular atrial fibrillation in 9 countries of the Asia-pacific region

Journal of Arrhythmia

Volumn 28, Issue 1, 2012, Pages 41-55

  Ogawa, Satoshi ^a   Aonuma, Kazutaka ^b   Huang, Dejia ^c   Huang, Jin Long ^d   Kalman, Jonathan ^e   Kamakura, Shiro ^f   Nair, Mohan ^g   Shin, Dong Gu ^h   Stiles, Martin ⁱ   Teo, Wee Siong ^j   Tse, Hung Fat ^k   Yamane, Teiichi ^l  

^a International University of Health and Welfare Mita Hospital   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c SICHUAN UNIVERSITY   (China)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^g Max Heart and Vascular Institute   (India)

^h Young Nam University Hospital   (South Korea)

ⁱ WAIKATO HOSPITAL   (New Zealand)

^j DEPARTMENT OF CARDIOLOGY   (Singapore)

^k UNIVERSITY OF HONG KONG   (Hong Kong)

^l JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Antithrombotic therapy; Aspirin; Atrial fibrillation; Dabigatoran; Warfarin

Indexed keywords

EID: 84870394278     PISSN: 18804276     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joa.2012.02.007     Document Type: Article

References (23)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the An Ticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. J Am Med Assoc 2001;285:2370-5.
2. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008;39:1901-19.
3. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee of Practice Guidelines (Writing
4. Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011;27:74-90.
5. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS2008): digest version. Circ J 2010;74:2479-500.
6. European Heart Rhythm Association. European Association for Cardio-Thoracic Surgery: guidelines for the management of atrial fibrillation: the Task Force for the Management ofAtrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31: 2369-429.
7. Wann LS, Curtis AB, Ellenbogen KA, et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011;57:1330-7 (2011).
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-6.
10. Miller VT, Rothrock JF, Pearce LA, et al. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke prevention in atrial fibrillation investigator groups. Neurology 1993;43:32-6.
11. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:429S-56S.
12. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrail fibrillation Clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomized controlled trial. Lancet 2006;367:1903-12.
13. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006;37:447-51.
14. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001;285:2864-70.
15. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009;151:297-305.
16. Puwanant S, Varr BC, Shrestha K, et al. Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol 2009;54:2032-9.
17. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342: d124. doi:10.1136/bmj.d124.
18. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000;35:183-7.
19. Wahl MJ. Dental surgery in anticoagulated patients. Archives of Internal Medicine 1998;158:1610-6.
20. Yasaka M, Naritomi H, Minematsu K, et al. Ischemic stroke associated with brief cessation of warfarin. Thromb Res 2006;118: 290-3.
21. Evans IL, Sayers MS, Gibbons AJ, et al. Can warfarin be continued during dental extraction? Result of a randomized controlled trial Br J Oral Maxillofacial Surg 2002;40:248-52.
22. Ardekian L, Gaspar R, Peled M, et al. Does low-dose aspirin therapy complicate oral surgical procedures? J Am Dent Assoc 2000;131: 331-5.
23. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W substudy. J Am Coll Cardiol 2007;50:2156-61.